All the above results indicate that TS might serve as a novel molecular marker for the prediction of disease progression and patient outcome in LUAD and many malignant tumours and may act as an effective marker to predict EGFR‐TKI resistance in LUAD. The gene discussed is TYMS; the disease is cancer.